DESTINY Breast Respond HER2-low Europe
NCT05945732
·
clinicaltrials.gov ↗
RECRUITING
Status
1155
Enrollment
INDUSTRY
Sponsor class
Conditions
Unresectable Breast Cancer
Metastatic Breast Cancer
HER2-low Expressing Breast Cancer
Interventions
DRUG:
Trastuzumab deruxtecan
Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company